Medtronic FQ1'27 preview – should be another step in right direction Maintain Rating: BUY | PO: 95.00 USD | Price: 91.27 USD Accessible version FQ1 seems good; focus on CAS durability and MDT ex CAS MDT guided FQ1'27 organic revenue growth of 6-6.5% excluding the extra selling week (extra week adds 500-600bps). Street models a mismatch of w/ and w/o extra week (not a clean comp). But when looking vs MDT's guide, we see a strong CAS quarter, healthy utilization, and expect a solid FQ1 top line performance. C ...